Loading…

Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis

Peritoneal metastasis is a primary cause of mortality in patients with gastric cancer. Urokinase-type plasminogen activator (uPA) has been demonstrated to be associated with tumor cell metastasis through the degradation of the extracellular matrix. The present study aimed to investigate the mechanis...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2016-06, Vol.11 (6), p.4208-4216
Main Authors: DING, YOUCHENG, ZHANG, HUI, LU, AIGUO, ZHOU, ZHUQING, ZHONG, MINGAN, SHEN, DONGWEI, WANG, XUJING, ZHU, ZHENGGANG
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943
cites cdi_FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943
container_end_page 4216
container_issue 6
container_start_page 4208
container_title Oncology letters
container_volume 11
creator DING, YOUCHENG
ZHANG, HUI
LU, AIGUO
ZHOU, ZHUQING
ZHONG, MINGAN
SHEN, DONGWEI
WANG, XUJING
ZHU, ZHENGGANG
description Peritoneal metastasis is a primary cause of mortality in patients with gastric cancer. Urokinase-type plasminogen activator (uPA) has been demonstrated to be associated with tumor cell metastasis through the degradation of the extracellular matrix. The present study aimed to investigate the mechanisms of the uPA system in gastric cancer with peritoneal metastasis. Expression of uPA, uPA receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) in four gastric cell lines (AGS, SGC7901, MKN45 and MKN28) was measured by semiquantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay and western blotting. uPA activity was detected using a uPA activity kit. Peritoneal implantation models of rats were established by injecting four gastric cancer cell lines for the selection of the cancer cells with a high planting potential. Biological behaviors, including adhesion, migration and invasion, were determined using a methyl thiazolyl tetrazolium assay. Expression of the uPA system was observed to be highest in the SGC7901 cells among the four gastric cell lines. uPA activity was observed to be highest in the MKN45 cells and lowest in the AGS cells. Furthermore, peritoneal implantation analysis demonstrated that no peritoneal tumors were identified in the AGS cells, whilst the tumor masses observed in the SGC7901 and MKN45 cells were of different sizes. The survival times of the rats injected with the MKN28 and SGC7901 cells were longer than those of the rats injected with the MKN45 cells. Antibodies for uPA, uPAR and PAI-1 in the uPA system had the ability to inhibit the adhesion, migration and invasion of peritoneal metastasis in the gastric cancer cells. The results of the present study demonstrated that the uPA system was positively associated with peritoneal metastasis in gastric cancer.
doi_str_mv 10.3892/ol.2016.4498
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4888090</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A455488975</galeid><sourcerecordid>A455488975</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943</originalsourceid><addsrcrecordid>eNptksFvFCEUxidGY5vam2dDojEenBWYGQYuTZqmVZNNetEzYZg3u1QGRmBq9r-X6da1a4QDBH7ve_DlK4rXBK8qLugnb1cUE7aqa8GfFaekFbQkmNPnh31bnxTnMd7hPBpGOGcvixPaVqRqGT8tuuthAJ2QH9Ac_A_jVIQy7SZAk1VxNM5vwCGlk7lXyQcUdzHBiIxDGxVTMBpp5TQE9MukLZogmOQdKItGSBlQ0cRXxYtB2Qjnj-tZ8f3m-tvVl3J9-_nr1eW61E0lUgm16FrdVwMTfccpYME17RraciJIm9_d1zVwNnAFGiiDjLUkkwPHQIioq7PiYq87zd0IvQaXgrJyCmZUYSe9MvL4xpmt3Ph7WXPOscBZ4MOjQPA_Z4hJjiZqsFY58HOUhFPGhKC4yejbf9A7PweXvyeJqDJW1YT9pTbKgjRu8LmvXkTlZd00ua9oF63Vf6g8exiNzm4OJp8fFbx_UrDNbqdt9HZOxrt4DH7cgzr4GAMMBzMIlkt-pLdyyY9c8pPxN08NPMB_0pKBd3sgTsr1pvfxwNyuS5zng85vXYDMKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932663416</pqid></control><display><type>article</type><title>Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis</title><source>PubMed Central</source><creator>DING, YOUCHENG ; ZHANG, HUI ; LU, AIGUO ; ZHOU, ZHUQING ; ZHONG, MINGAN ; SHEN, DONGWEI ; WANG, XUJING ; ZHU, ZHENGGANG</creator><creatorcontrib>DING, YOUCHENG ; ZHANG, HUI ; LU, AIGUO ; ZHOU, ZHUQING ; ZHONG, MINGAN ; SHEN, DONGWEI ; WANG, XUJING ; ZHU, ZHENGGANG</creatorcontrib><description>Peritoneal metastasis is a primary cause of mortality in patients with gastric cancer. Urokinase-type plasminogen activator (uPA) has been demonstrated to be associated with tumor cell metastasis through the degradation of the extracellular matrix. The present study aimed to investigate the mechanisms of the uPA system in gastric cancer with peritoneal metastasis. Expression of uPA, uPA receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) in four gastric cell lines (AGS, SGC7901, MKN45 and MKN28) was measured by semiquantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay and western blotting. uPA activity was detected using a uPA activity kit. Peritoneal implantation models of rats were established by injecting four gastric cancer cell lines for the selection of the cancer cells with a high planting potential. Biological behaviors, including adhesion, migration and invasion, were determined using a methyl thiazolyl tetrazolium assay. Expression of the uPA system was observed to be highest in the SGC7901 cells among the four gastric cell lines. uPA activity was observed to be highest in the MKN45 cells and lowest in the AGS cells. Furthermore, peritoneal implantation analysis demonstrated that no peritoneal tumors were identified in the AGS cells, whilst the tumor masses observed in the SGC7901 and MKN45 cells were of different sizes. The survival times of the rats injected with the MKN28 and SGC7901 cells were longer than those of the rats injected with the MKN45 cells. Antibodies for uPA, uPAR and PAI-1 in the uPA system had the ability to inhibit the adhesion, migration and invasion of peritoneal metastasis in the gastric cancer cells. The results of the present study demonstrated that the uPA system was positively associated with peritoneal metastasis in gastric cancer.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2016.4498</identifier><identifier>PMID: 27313768</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Care and treatment ; Complications and side effects ; Dehydrogenases ; Gastric cancer ; Health aspects ; Medical prognosis ; Metastasis ; Mortality ; Oncology ; peritoneal metastasis ; Prostate cancer ; Proteases ; Stem cells ; Stomach cancer ; Studies ; Thrombolytic drugs ; urokinase-type plasminogen activator</subject><ispartof>Oncology letters, 2016-06, Vol.11 (6), p.4208-4216</ispartof><rights>Copyright © 2016, Spandidos Publications</rights><rights>COPYRIGHT 2016 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2016</rights><rights>Copyright © 2016, Spandidos Publications 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943</citedby><cites>FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888090/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888090/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27313768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DING, YOUCHENG</creatorcontrib><creatorcontrib>ZHANG, HUI</creatorcontrib><creatorcontrib>LU, AIGUO</creatorcontrib><creatorcontrib>ZHOU, ZHUQING</creatorcontrib><creatorcontrib>ZHONG, MINGAN</creatorcontrib><creatorcontrib>SHEN, DONGWEI</creatorcontrib><creatorcontrib>WANG, XUJING</creatorcontrib><creatorcontrib>ZHU, ZHENGGANG</creatorcontrib><title>Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Peritoneal metastasis is a primary cause of mortality in patients with gastric cancer. Urokinase-type plasminogen activator (uPA) has been demonstrated to be associated with tumor cell metastasis through the degradation of the extracellular matrix. The present study aimed to investigate the mechanisms of the uPA system in gastric cancer with peritoneal metastasis. Expression of uPA, uPA receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) in four gastric cell lines (AGS, SGC7901, MKN45 and MKN28) was measured by semiquantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay and western blotting. uPA activity was detected using a uPA activity kit. Peritoneal implantation models of rats were established by injecting four gastric cancer cell lines for the selection of the cancer cells with a high planting potential. Biological behaviors, including adhesion, migration and invasion, were determined using a methyl thiazolyl tetrazolium assay. Expression of the uPA system was observed to be highest in the SGC7901 cells among the four gastric cell lines. uPA activity was observed to be highest in the MKN45 cells and lowest in the AGS cells. Furthermore, peritoneal implantation analysis demonstrated that no peritoneal tumors were identified in the AGS cells, whilst the tumor masses observed in the SGC7901 and MKN45 cells were of different sizes. The survival times of the rats injected with the MKN28 and SGC7901 cells were longer than those of the rats injected with the MKN45 cells. Antibodies for uPA, uPAR and PAI-1 in the uPA system had the ability to inhibit the adhesion, migration and invasion of peritoneal metastasis in the gastric cancer cells. The results of the present study demonstrated that the uPA system was positively associated with peritoneal metastasis in gastric cancer.</description><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Dehydrogenases</subject><subject>Gastric cancer</subject><subject>Health aspects</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Oncology</subject><subject>peritoneal metastasis</subject><subject>Prostate cancer</subject><subject>Proteases</subject><subject>Stem cells</subject><subject>Stomach cancer</subject><subject>Studies</subject><subject>Thrombolytic drugs</subject><subject>urokinase-type plasminogen activator</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNptksFvFCEUxidGY5vam2dDojEenBWYGQYuTZqmVZNNetEzYZg3u1QGRmBq9r-X6da1a4QDBH7ve_DlK4rXBK8qLugnb1cUE7aqa8GfFaekFbQkmNPnh31bnxTnMd7hPBpGOGcvixPaVqRqGT8tuuthAJ2QH9Ac_A_jVIQy7SZAk1VxNM5vwCGlk7lXyQcUdzHBiIxDGxVTMBpp5TQE9MukLZogmOQdKItGSBlQ0cRXxYtB2Qjnj-tZ8f3m-tvVl3J9-_nr1eW61E0lUgm16FrdVwMTfccpYME17RraciJIm9_d1zVwNnAFGiiDjLUkkwPHQIioq7PiYq87zd0IvQaXgrJyCmZUYSe9MvL4xpmt3Ph7WXPOscBZ4MOjQPA_Z4hJjiZqsFY58HOUhFPGhKC4yejbf9A7PweXvyeJqDJW1YT9pTbKgjRu8LmvXkTlZd00ua9oF63Vf6g8exiNzm4OJp8fFbx_UrDNbqdt9HZOxrt4DH7cgzr4GAMMBzMIlkt-pLdyyY9c8pPxN08NPMB_0pKBd3sgTsr1pvfxwNyuS5zng85vXYDMKw</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>DING, YOUCHENG</creator><creator>ZHANG, HUI</creator><creator>LU, AIGUO</creator><creator>ZHOU, ZHUQING</creator><creator>ZHONG, MINGAN</creator><creator>SHEN, DONGWEI</creator><creator>WANG, XUJING</creator><creator>ZHU, ZHENGGANG</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160601</creationdate><title>Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis</title><author>DING, YOUCHENG ; ZHANG, HUI ; LU, AIGUO ; ZHOU, ZHUQING ; ZHONG, MINGAN ; SHEN, DONGWEI ; WANG, XUJING ; ZHU, ZHENGGANG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Dehydrogenases</topic><topic>Gastric cancer</topic><topic>Health aspects</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Oncology</topic><topic>peritoneal metastasis</topic><topic>Prostate cancer</topic><topic>Proteases</topic><topic>Stem cells</topic><topic>Stomach cancer</topic><topic>Studies</topic><topic>Thrombolytic drugs</topic><topic>urokinase-type plasminogen activator</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DING, YOUCHENG</creatorcontrib><creatorcontrib>ZHANG, HUI</creatorcontrib><creatorcontrib>LU, AIGUO</creatorcontrib><creatorcontrib>ZHOU, ZHUQING</creatorcontrib><creatorcontrib>ZHONG, MINGAN</creatorcontrib><creatorcontrib>SHEN, DONGWEI</creatorcontrib><creatorcontrib>WANG, XUJING</creatorcontrib><creatorcontrib>ZHU, ZHENGGANG</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DING, YOUCHENG</au><au>ZHANG, HUI</au><au>LU, AIGUO</au><au>ZHOU, ZHUQING</au><au>ZHONG, MINGAN</au><au>SHEN, DONGWEI</au><au>WANG, XUJING</au><au>ZHU, ZHENGGANG</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>11</volume><issue>6</issue><spage>4208</spage><epage>4216</epage><pages>4208-4216</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Peritoneal metastasis is a primary cause of mortality in patients with gastric cancer. Urokinase-type plasminogen activator (uPA) has been demonstrated to be associated with tumor cell metastasis through the degradation of the extracellular matrix. The present study aimed to investigate the mechanisms of the uPA system in gastric cancer with peritoneal metastasis. Expression of uPA, uPA receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) in four gastric cell lines (AGS, SGC7901, MKN45 and MKN28) was measured by semiquantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay and western blotting. uPA activity was detected using a uPA activity kit. Peritoneal implantation models of rats were established by injecting four gastric cancer cell lines for the selection of the cancer cells with a high planting potential. Biological behaviors, including adhesion, migration and invasion, were determined using a methyl thiazolyl tetrazolium assay. Expression of the uPA system was observed to be highest in the SGC7901 cells among the four gastric cell lines. uPA activity was observed to be highest in the MKN45 cells and lowest in the AGS cells. Furthermore, peritoneal implantation analysis demonstrated that no peritoneal tumors were identified in the AGS cells, whilst the tumor masses observed in the SGC7901 and MKN45 cells were of different sizes. The survival times of the rats injected with the MKN28 and SGC7901 cells were longer than those of the rats injected with the MKN45 cells. Antibodies for uPA, uPAR and PAI-1 in the uPA system had the ability to inhibit the adhesion, migration and invasion of peritoneal metastasis in the gastric cancer cells. The results of the present study demonstrated that the uPA system was positively associated with peritoneal metastasis in gastric cancer.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>27313768</pmid><doi>10.3892/ol.2016.4498</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1792-1074
ispartof Oncology letters, 2016-06, Vol.11 (6), p.4208-4216
issn 1792-1074
1792-1082
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4888090
source PubMed Central
subjects Care and treatment
Complications and side effects
Dehydrogenases
Gastric cancer
Health aspects
Medical prognosis
Metastasis
Mortality
Oncology
peritoneal metastasis
Prostate cancer
Proteases
Stem cells
Stomach cancer
Studies
Thrombolytic drugs
urokinase-type plasminogen activator
title Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T23%3A04%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20urokinase-type%20plasminogen%20activator%20system%20in%20gastric%20cancer%20with%20peritoneal%20metastasis&rft.jtitle=Oncology%20letters&rft.au=DING,%20YOUCHENG&rft.date=2016-06-01&rft.volume=11&rft.issue=6&rft.spage=4208&rft.epage=4216&rft.pages=4208-4216&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2016.4498&rft_dat=%3Cgale_pubme%3EA455488975%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c539t-e49b7cd3f69db82e098c2b52781917886d44e86f8aece26e69d71db8f80e11943%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1932663416&rft_id=info:pmid/27313768&rft_galeid=A455488975&rfr_iscdi=true